XNYS · Healthcare Plans
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$70.19+2.41%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
52/100
Moderate
Score components
TickerWhale View
Centene scores 52 out of 100 overall, which we rate moderate. Valuation is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Valuation
- Sentiment Signal
What to watch
- Quality & growth
- Risk
Quality & growth
30%5Weak
- Revenue growth 13.8%
- EPS growth -358.7%
Valuation
25%98Strong
- P/E -6.8
- EV/Sales 0.1
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
#317 by market cap in our coverage · ~61,100 employees · Listed 2001-12-13 · www.centene.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#90 / 139sector rank by TickerWhale Score
TickerWhale Score 52 vs sector average 54.6 (-2.6)
Revenue growth (industry)Top 38%
Gross margin (industry)Top 38%
Return on equity (industry)Top 100%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
71/100Strong vs universe
Ranks 71st of 100 covered names on our technical composite — the composite itself scores 69/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
3 buy · 1 sell · 4 neutral of 8 votes
TickerWhale rates CNC's technical setup strong — 71st percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
8 / 9constructive
- vs 200-day+24.9%
- vs 50-day+5.0%
Momentum
Mixed
- RSI (14)53 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength17· weak trend
- MACD (12,26,9)sell(histogram -0.050)
How the classic verdict is reached
Moving averages (9) agree on buy — 8 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 1 sell · 4 neutral.
Result — 3 buy vs 1 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)-6.8 · TTM loss
- P/S (TTM)0.2
- P/B1.5
- EV/EBITDA—
- EV/Sales0.1
- PEG—
Profitability & returns
- Gross margin21.9%
- Net margin-2.5%
- ROE-23.2%
- Debt/Equity0.71
Growth
- Revenue growth (YoY)13.8%
- EPS growth (YoY)-358.7%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $34.9B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $194.8B | $163.1B | $154.0B |
| Gross profit | $13.9B | $16.8B | $17.3B |
| Operating income | -$7.6B | $3.2B | $2.9B |
| Net income | -$6.7B | $3.3B | $2.7B |
| EPS (diluted) | $-13.53 | $6.31 | $4.95 |
| Free cash flow | $4.3B | -$490M | $7.3B |
| Cash | $17.9B | $14.1B | $17.2B |
| Total debt | $17.4B | $18.5B | $17.8B |
| Equity | $20.0B | $26.4B | $25.8B |
| Net debt | -$487M | $4.5B | $636M |
| Debt / equity | 0.87 | 0.70 | 0.69 |
| Liabilities / assets | 0.74 | 0.68 | 0.69 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNCCurrentCentene | 52 | 69 | -6.8 | — | 1.5 | 0.1 | $70.19 | +2.41% | +13.8% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.